Proteomics: A strategy to understand the novel targets in protein misfolding and cancer therapy

Expert Review of Proteomics

Volumn 7, Issue 4, 2010, Pages 613-623

  Nagaraj, Nagathihalli S ^a   Singh, Om V ^b   Merchant, Nipun B ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cancer; cancer targets; chaperones; heat shock proteins; protein misfolding; proteomics

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 2 PHENYLETHYNEUSULFONAMIDE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; CHAPERONE; CURCUMIN; DEFOROLIMUS; EVEROLIMUS; GELDANAMYCIN; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; PROTEASOME; PROTEIN P53; PROTEIN TYROSINE KINASE; STA 1474; STA 9090; TANESPIMYCIN; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CARCINOID; CLINICAL TRIAL; DRUG TARGETING; ENDOMETRIUM CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC STABILITY; GLIOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MICROENVIRONMENT; MYELOMA; NONHUMAN; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PANCREAS ISLET CELL TUMOR; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEOMICS; REVIEW; SARCOMA; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN FOLDING; PROTEOMICS; TUMOR SUPPRESSOR PROTEINS;

EID: 77954998449     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.70     Document Type: Review

References (131)

1. Hardesty B, Kramer G. Folding of a nascent peptide on the ribosome. Prog. Nucleic Acid Res. Mol. Biol. 66, 41-66 (2001).
2. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 125(3), 443-451 (2006).
3. Dobson CM. Protein folding and misfolding. Nature 426(6968), 884-890 (2003).
4. Luheshi LM, Dobson CM. Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett. 583(16), 2581-2586 (2009).
5. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 426(6968), 905-909 (2003).
6. So AY, de la Fuente E, Walter P, Shuman M, Bernales S. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev. 28(1-2), 219-223 (2009).
7. Blagosklonny MV. Loss of function and p53 protein stabilization. Oncogene 15(16), 1889-1893 (1997).
8. Hoehn GT, Suffredini AF. Proteomics. Crit. Care Med. 33(12 Suppl.), S444-S448 (2005).
9. Alessandro R, Fontana S, Kohn E, De Leo G. Proteomic strategies and their application in cancer research. Tumori 91(6), 447-455 (2005).
10. Yarmush ML, Jayaraman A. Advances in proteomic technologies. Annu. Rev. Biomed. Eng. 4, 349-373 (2002).
11. Bottoni P, Giardina B, Scatena R. Proteomic profiling of heat shock proteins: an emerging molecular approach with direct pathophysiological and clinical implications. Proteom. Clin. Appl. 3(6), 636-653 (2009).
12. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997).
13. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal. Bioanal. Chem. 382(3), 669-678 (2005).
14. DeSouza L, Diehl G, Rodrigues MJ et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 4(2), 377-386 (2005).
15. Pastwa E, Somiari SB, Czyz M, Somiari RI. Proteomics in human cancer research. Proteom. Clin. Appl. 1(1), 4-17 (2007).
16. Hariharan D, Weeks ME, Crnogorac-Jurcevic T. Application of proteomics in cancer gene profiling: two-dimensional difference in gel electrophoresis (2D-DIGE). Methods Mol. Biol. 576, 197-211 (2010).
17. Old WM, Meyer-Arendt K, Aveline-Wolf L et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell. Proteomics 4(10), 1487-1502 (2005).
18. Scott MD, Frydman J. Aberrant protein folding as the molecular basis of cancer. Methods Mol. Biol. 232, 67-76 (2003).
19. Morano KA. New tricks for an old dog: the evolving world of Hsp70. Ann. NY Acad. Sci. 1113, 1-14 (2007).
20. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 70, 603-647 (2001).
21. Kajiro M, Hirota R, Nakajima Y et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol. 11(3), 312-319 (2009).
22. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006).
23. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 25(48), 6373-6383 (2006).
24. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31(3), 164-172 (2006).
25. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br. J. Cancer 100(10), 1523-1529 (2009).
26. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov. Today 13(1-2), 38-43 (2008).
27. Vousden KH, Lane DP. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8(4), 275-283 (2007).
28. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582 (2008).
29. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19(3), 370-378 (2000).
30. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26(15), 2243-2254 (2007).
31. Walerych D, Kudla G, Gutkowska M et al. Hsp90 chaperones wild-type p53 tumor suppressor protein. J. Biol. Chem. 279(47), 48836-48845 (2004).
32. Rudiger S, Freund SM, Veprintsev DB, Fersht AR. CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc. Natl Acad. Sci. USA 99(17), 11085-11090 (2002).
33. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 19(49), 5636-5642 (2000).
34. Yeatman TJ. A renaissance for SRC. Nat. Rev. Cancer 4(6), 470-480 (2004).
35. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337-358 (2003).
36. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist 14(7), 667-678 (2009).
37. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513-609 (1997).
38. Falsone SF, Leptihn S, Osterauer A, Haslbeck M, Buchner J. Oncogenic mutations reduce the stability of SRC kinase. J. Mol. Biol. 344(1), 281-291 (2004).
39. Bijlmakers MJ, Marsh M. Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol. Biol. Cell 11(5), 1585-1595 (2000).
40. Xu Y, Lindquist S. Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Natl Acad. Sci. USA 90(15), 7074-7078 (1993).
41. Xu Y, Singer MA, Lindquist S. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl Acad. Sci. USA 96(1), 109-114 (1999).
42. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62(6), 670-684 (2005).
43. Hartson SD, Ottinger EA, Huang W, Barany G, Burn P, Matts RL. Modular folding and evidence for phosphorylation-induced stabilization of an hsp90-dependent kinase. J. Biol. Chem. 273(14), 8475-8482 (1998).
44. Demand J, Luders J, Hohfeld J. The carboxy-terminal domain of Hsc70 provides binding sites for a distinct set of chaperone cofactors. Mol. Cell. Biol. 18(4), 2023-2028 (1998).
45. Ballinger CA, Connell P, Wu Y et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19(6), 4535-4545 (1999).
46. McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 8(4), 303-308 (2003).
47. Connell P, Ballinger CA, Jiang J et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3(1), 93-96 (2001).
48. Voellmy R. On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones 9(2), 122-133 (2004).
49. Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med. Chem. 1(2), 267-283 (2009).
50. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296(5576), 2232-2235 (2002).
51. Arthur JC, Lich JD, Aziz RK, Kotb M, Ting JP. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kB-inducing kinase. J. Immunol. 179(9), 6291-6296 (2007).
52. Weis F, Moullintraffort L, Heichette C, Chretien D, Garnier C. The 90-kDa heat shock protein Hsp90 protects tubulin against thermal denaturation. J. Biol. Chem. 285(13), 9525-9534 (2010).
53. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of HSP89 a in human breast cancer. Int. J. Cancer 50(3), 409-415 (1992).
54. Yufu Y, Nishimura J, Nawata H. High constitutive expression of heat shock protein 90 a in human acute leukemia cells. Leuk. Res. 16(6-7), 597-605 (1992).
55. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. 146(6), 769-780 (2005).
56. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5(10), 761-772 (2005).
57. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956), 407-410 (2003).
58. Maroney AC, Marugan JJ, Mezzasalma TM et al. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 45(17), 5678-5685 (2006).
59. Didelot C, Lanneau D, Brunet M et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr. Med. Chem. 14(27), 2839-2847 (2007).
60. Kramer G, Boehringer D, Ban N, Bukau B. The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat. Struct. Mol. Biol. 16(6), 589-597 (2009).
61. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10(2), 86-103 (2005).
62. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9(8) (2010).
63. Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr. Top. Med. Chem. 6(11), 1215-1225 (2006).
64. Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann. NY Acad. Sci. 926, 122-125 (2000).
65. Parmiani G, Testori A, Maio M et al. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. 10(24), 8142-8146 (2004).
66. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol. 81(1), 15-27 (2007). (Pubitemid 46021247)
67. Loewith R, Jacinto E, Wullschleger S et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10(3), 457-468 (2002).
68. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6(9), 729-734 (2006).
69. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4(5), 335-348 (2004).
70. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12(1), 9-22 (2007).
71. Reymond MA, Schlegel W. Proteomics in cancer. Adv. Clin. Chem. 44, 103-142 (2007).
72. Sun Y, Zang Z, Xu X et al. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int. J. Mol. Sci. 11(4), 1423-1433 (2010).
73. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14(3), 250-262 (2008).
74. Bottoni P, Giardina B, Martorana GE et al. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. J. Cell. Mol. Med. 9(2), 462-467 (2005).
75. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4(10), 3276-3287 (2004).
76. Grossmann ME, Madden BJ, Gao F et al. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res. 297(1), 108-117 (2004).
77. Fujita Y, Nakanishi T, Miyamoto Y et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 263(2), 280-290 (2008).
78. Hayashi E, Kuramitsu Y, Okada F et al. Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 5(4), 1024-1032 (2005).
79. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 7(15), 2603-2616 (2007).
80. Maloney A, Clarke PA, Naaby-Hansen S et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67(7), 3239-3253 (2007).
81. Te J, Jia L, Rogers J, Miller A, Hartson SD. Novel subunits of the mammalian Hsp90 signal transduction chaperone. J. Proteome Res. 6(5), 1963-1973 (2007).
82. Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, Kungl AJ. A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett. 579(28), 6350-6354 (2005).
83. Falsone SF, Gesslbauer B, Rek A, Kungl AJ. A proteomic approach towards the Hsp90-dependent ubiquitinylated proteome. Proteomics 7(14), 2375-2383 (2007).
84. Tsaytler PA, Krijgsveld J, Goerdayal SS, Rudiger S, Egmond MR. Novel Hsp90 partners discovered using complementary proteomic approaches. Cell Stress Chaperones 14(6), 629-638 (2009).
85. Gano JJ, Simon JA. A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein. Mol. Cell. Proteomics 9(2), 255-270 (2010).
86. Chenau J, Michelland S, de Fraipont F et al. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J. Proteome Res. 8(10), 4579-4591 (2009).
87. Lee K, Wang T, Paszczynski AJ, Daoud SS. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells. Biochem. Biophys. Res. Commun. 349(3), 1117-1124 (2006).
88. Shor B, Wu J, Shakey Q et al. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J. Biol. Chem. 285(20), 15380-15392 (2010).
89. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid b oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282(14), 10311-10324 (2007).
90. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr. Opin. Drug Discov. Devel. 9(4), 483-495 (2006).
91. McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66(22), 10967-10975 (2006).
92. McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces Hsp70 and prevents a-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 321(3), 665-669 (2004).
93. Hay DG, Sathasivam K, Tobaben S et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13(13), 1389-1405 (2004).
94. Kim YS, Alarcon SV, Lee S et al. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9(15), 1479-1492 (2009).
95. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410(3), 439-453 (2008).
96. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 17(6), 2225-2235 (2009).
97. Patury S, Miyata Y, Gestwicki JE. Pharmacological targeting of the Hsp70 chaperone. Curr. Top. Med. Chem. 9(15), 1337-1351 (2009).
98. Guo F, Rocha K, Bali P et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65(22), 10536-10544 (2005).
99. Lin TY, Bear M, Du Z et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp. Hematol. 36(10), 1266-1277 (2008).
100. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443(7113), 780-786 (2006).
101. Selivanova G, Iotsova V, Okan I et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3(6), 632-638 (1997).
102. Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell 36(1), 15-27 (2009).
103. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci. Signal. 2(67), pe24 (2009).
104. Kapoor A. Inhibition of mTOR in kidney cancer. Curr. Oncol. 16(Suppl. 1), S33-S39 (2009).
105. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26(3), 361-367 (2008).
106. Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9(17), 1-34 (2007).
107. Saito Y, Yokota T, Mitani T et al. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J. Biol. Chem. 280(52), 42826-42830 (2005).
108. Banerji U, O'Donnell A, Scurr M et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23(18), 4152-4161 (2005).
109. Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a Phase I dose-escalation study. J. Clin. Oncol. 25(34), 5410-5417 (2007).
110. Castagna A, Antonioli P, Astner H et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4(10), 3246-3267 (2004).
111. Short DM, Heron ID, Birse-Archbold JL, Kerr LE, Sharkey J, McCulloch J. Apoptosis induced by staurosporine alters chaperone and endoplasmic reticulum proteins: identification by quantitative proteomics. Proteomics 7(17), 3085-3096 (2007).
112. Hu W, Wu W, Verschraegen CF et al. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 3(10), 1904-1911 (2003).
113. Nollen EA, Garcia SM, van Haaften G et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl Acad. Sci. USA 101(17), 6403-6408 (2004).
114. Nagaraj NS. Evolving 'omics' technologies for diagnostics of head and neck cancer. Brief Funct. Genomic Proteomic 8(1), 49-59 (2009).
115. Nagaraj NS, Singh OV. Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer. Expert Opin. Med. Diagn. 3(2), 167-180 (2009).
116. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr. Opin. Pediatr. 14(1), 5-11 (2002).
117. Ivan M, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11(1), 27-34 (2001).
118. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol. Cell. Biol. 22(4), 1150-1157 (2002).
119. Usmani SZ, Bona R, Li Z. 17 AAG for HSP90 inhibition in cancer -from bench to bedside. Curr. Mol. Med. 9(5), 654-664 (2009).
120. Kubo T, Kobayashi N, Jida M et al. The antitumor effect of orally active heat shock protein 90 inhibitor, 17-DMAG, on the growth of gefitinib-resistant non-small cell lung cancer. J. Clin. Oncol. (Meeting Abstracts) 27(15 Suppl.), (2009) (Abstract e22064).
121. Pacey SC, Wilson R, Walton M et al. A Phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J. Clin. Oncol. (Meeting Abstracts) 27(15 Suppl.), (2009) (Abstract 3534).
122. McCleese JK, Bear MD, Fossey SL et al. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 125(12), 2792-2801 (2009).
123. Zheng FF, Kuduk SD, Chiosis G et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 60(8), 2090-2094 (2000).
124. Oza AM, Elit L, Biagi J et al. A Phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer -NCICCTG IND 160. Clinical Cancer Res. 11(24), 9099s-9099s (2005).
125. Roccaro AM, Leduc R, Nelson M et al. Phase I trial of CCI-779 and weekly bortezomib in relapsed and/or refractory multiple myeloma. Clin. Lymphoma Myelom. 9, S86-S86 (2009).
126. Wen P, Chang S, Kuhn J et al. Phase I/II study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). Neuro. Oncol. 11(2), 232-232 (2009).
127. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(23), 5314-5322 (2005).
128. Baselga J, Semiglazov V, Van Dam P et al. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER plus breast cancer. Breast Cancer Res. 106, S107-S107 (2007).
129. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311-4318 (2008).
130. Yardley DA, Seiler M, Ray-Coquard I et al. Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter Phase 2 clinical trial. Cancer Res. 69(24), 676s-676s (2009).
131. Clinical Trials website www.clinicaltrials.gov